En kombinasjon av to for tiden godkjente legemidler for å forbedre behandlingen av schizofreni
Studieoversikt
Status
Status
Forhold
Forhold
Intervensjon / Behandling
Intervensjon / Behandling
Studietype
Studietype
Fase
Fase
- Fase 2
- Fase 1
Kontakter og plasseringer
Studiesteder
-
-
California
-
Cerritos, California, Forente stater
- "For additional information regarding investigative sites for this trial, contact the Clinical Trials Support Center at (1-877-285-4559) or speak with your personal physician."
-
Chula Vista, California, Forente stater
- "For additional information regarding investigative sites for this trial, contact the Clinical Trials Support Center at (1-877-285-4559) or speak with your personal physician.
-
Garden Grove, California, Forente stater
- For additional information regarding investigative sites for this trial, contact the Clinical Trials Support Center at 1-877-CTLILLY(1-877-285-4559) or speak with your personal physician.
-
San Diego, California, Forente stater
- "For additional information regarding investigative sites for this trial, contact the Clinical Trials Support Center at (1-877-285-4559) or speak with your personal physician."
-
-
Connecticut
-
New Haven, Connecticut, Forente stater
- "For additional information regarding investigative sites for this trial, contact the Clinical Trials Support Center at (1-877-285-4559) or speak with your personal physician."
-
New Haven, Connecticut, Forente stater
- For additional information regarding investigative sites for this trial, contact the Clinical Trials Support Center at 1-877-CTLILLY(1-877-285-4559) or speak with your personal physician.
-
-
Georgia
-
Atlanta, Georgia, Forente stater
- "For additional information regarding investigative sites for this trial, contact the Clinical Trials Support Center at (1-877-285-4559) or speak with your personal physician."
-
-
Illinois
-
Chicago, Illinois, Forente stater
- "For additional information regarding investigative sites for this trial, contact the Clinical Trials Support Center at (1-877-285-4559) or speak with your personal physician."
-
-
Indiana
-
Indianapolis, Indiana, Forente stater
- "For additional information regarding investigative sites for this trial, contact the Clinical Trials Support Center at (1-877-285-4559) or speak with your personal physician."
-
-
Iowa
-
Iowa City, Iowa, Forente stater
- "For additional information regarding investigative sites for this trial, contact the Clinical Trials Support Center at (1-877-285-4559) or speak with your personal physician."
-
-
Minnesota
-
Minneapolis, Minnesota, Forente stater
- "For additional information regarding investigative sites for this trial, contact the Clinical Trials Support Center at (1-877-285-4559) or speak with your personal physician."
-
-
New Hampshire
-
Lebanon, New Hampshire, Forente stater
- "For additional information regarding investigative sites for this trial, contact the Clinical Trials Support Center at (1-877-285-4559) or speak with your personal physician."
-
-
New York
-
New York, New York, Forente stater
- "For additional information regarding investigative sites for this trial, contact the Clinical Trials Support Center at (1-877-285-4559) or speak with your personal physician."
-
-
North Carolina
-
Butner, North Carolina, Forente stater
- "For additional information regarding investigative sites for this trial, contact the Clinical Trials Support Center at (1-877-285-4559) or speak with your personal physician."
-
Chapel Hill, North Carolina, Forente stater
- "For additional information regarding investigative sites for this trial, contact the Clinical Trials Support Center at (1-877-285-4559) or speak with your personal physician."
-
-
Oklahoma
-
Okalahoma City, Oklahoma, Forente stater
- "For additional information regarding investigative sites for this trial, contact the Clinical Trials Support Center at (1-877-285-4559) or speak with your personal physician."
-
-
Texas
-
Austin, Texas, Forente stater
- "For additional information regarding investigative sites for this trial, contact the Clinical Trials Support Center at (1-877-285-4559) or speak with your personal physician."
-
Irvin, Texas, Forente stater
- "For additional information regarding investigative sites for this trial, contact the Clinical Trials Support Center at (1-877-285-4559) or speak with your personal physician."
-
Irving, Texas, Forente stater
- For additional information regarding investigative sites for this trial, contact the Clinical Trials Support Center at 1-877-CTLILLY(1-877-285-4559) or speak with your personal physician.
-
San Antonio, Texas, Forente stater
- "For additional information regarding investigative sites for this trial, contact the Clinical Trials Support Center at (1-877-285-4559) or speak with your personal physician."
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
Inklusjonskriterier:
- Må ha en klinisk diagnose schizofreni
- Må være minst 18 år og ikke eldre enn 55 år
- Må ha vært stabil på en dose Abilify, Risperdal, Seroquel eller Zyprexa de siste 8 ukene
- Kvinner i fertil alder må bruke en medisinsk akseptert prevensjon
- Må kunne svelge kapsler
Ekskluderingskriterier:
- Har andre alvorlige helseproblemer enn schizofreni
- Tar et antidepressivt middel mot depresjon
- Tar insulin for diabetes
- Har en historie med alkohol- eller narkotikaavhengighet (unntatt nikotin og koffein) i løpet av de siste 6 månedene
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Behandling
Samarbeidspartnere og etterforskere
Sponsor
Sponsor
Studierekorddatoer
Datoer for studieregistrering
Først innsendt
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Anslag)
Først lagt ut
Oppdateringer av studieposter
Sist oppdatering lagt ut (Anslag)
Sist oppdatering lagt ut
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Ytterligere relevante MeSH-vilkår
- Psykiske lidelser
- Schizofrenispektrum og andre psykotiske lidelser
- Schizofreni
- Fysiologiske effekter av legemidler
- Adrenerge midler
- Nevrotransmittere agenter
- Molekylære mekanismer for farmakologisk virkning
- Sentralnervesystemdepressiva
- Autonome agenter
- Agenter fra det perifere nervesystemet
- Antiemetika
- Gastrointestinale midler
- Antipsykotiske midler
- Beroligende midler
- Psykotropiske stoffer
- Serotoninopptakshemmere
- Nevrotransmitter opptakshemmere
- Membrantransportmodulatorer
- Serotoninmidler
- Adrenerge opptakshemmere
- Olanzapin
- Atomoksetinhydroklorid
Andre studie-ID-numre
Andre studie-ID-numre
- 8269 (CTEP)
- H6U-MC-HGLM
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .